IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and
Webcast on March 22, 2019
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it
will hold a conference call and webcast on Friday, March 22, 2019 at 8:00 a.m. ET to discuss the company’s 2018 fourth quarter and
fiscal year-end financial and operational results.
Financial analysts are invited to join the conference call by dialing (844) 461-9932 (U.S. and Canada) or (636) 812-6632
(international) using the conference ID: 9647179.
Other interested parties will be able to access the live audio webcast at this link:
https://ir.imv-inc.com/events-and-presentations. The webcast will be recorded and will then be available on the IMV website for
30 days following the call.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly
applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of
immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of
action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the
platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a
combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com
IMV Forward-Looking Statements
This press release contains forward-looking information under applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are
based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. IMV Inc. assumes no responsibility to update forward-looking statements in this
press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties and
those risks and uncertainties include, but are not limited to, our ability to access capital, the successful and timely completion
of clinical trials, the receipt of all regulatory approvals and other risks detailed from time to time in our ongoing quarterly
filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to
read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual
consolidated financial statements which are available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov/edgar.
MEDIA:
Andrea Cohen, Sam Brown Inc.
O: (917) 209-7163 E: andreacohen@sambrown.com
INVESTOR RELATIONS
Marc Jasmin, IMV Senior Director, Investor Relations and Communications
O: (902) 492-1819
M: (514) 917-9481 E: mjasmin@imv-inc.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
M: (415) 515-4572 E: patti.bank@westwicke.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190308005046/en/